~~U.S.~~UNITED ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q~~STATES

~~Mark~~SECURITIES ~~One~~AND EXCHANGE COMMISSION

[Washington, ~~X] QUARTERLY~~D.C. ~~REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~20549

~~For~~FORM ~~the quarterly period ended October 31, 2013~~10-Q

~~[ ] TRANSITION~~x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the ~~transition~~quarterly period ~~from~~ended October 31, ~~______ to _______~~2014

~~Commission File No. 333-187669~~or

~~ALPHALA~~¨ TRANSITION ~~CORP.~~REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~Nevada~~For ~~(State~~the ortransition ~~Other~~period ~~Jurisdiction~~from ~~of Incorporation or Organization) 5122 Primary Standard Industrial Classification Code Number~~______________ to______________

68Commission file number 333-~~0682594~~187669

~~IRS~~FV ~~Employer Identification~~PHARMA ~~Number~~INTERNATIONAL CORP. (Exact name of registrant as specified in its charter)

Darzinu 22 linija, 10 Majas

Nevada		68-0682594
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

203 – 29 Gervais Drive Toronto, Ontario, Canada		M3C 1Y9
(Address of principal executive offices)		(Zip Code)

~~Riga,~~(416) ~~Latvia LV~~444-~~1063~~4427

~~Tel.~~ (~~702)~~Registrant’s ~~605-0519~~telephone number, including area code)

(Issuer’s telephone number)

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X ] No[ ]

Indicate by check mark whether the registrant is a large accelerated filed, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years.

N/A

~~Indicate~~(Former byname, ~~checkmark~~former ~~whether~~address ~~the issuer has filed all documents~~ and ~~reports~~former ~~required to be filed by Section 12~~fiscal year, 13if ~~and~~changed ~~15(d)~~since oflast ~~the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes[ ] No[ ]~~report)

~~Applicable~~Indicate by ~~Only~~check mark whether the registrant (1) has filed all reports required to ~~Corporate~~be ~~Registrants~~filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the ~~number~~registrant ofhas ~~shares~~submitted ~~outstanding~~electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of ~~each~~Regulation S-T (§232.405 of this chapter) during the preceding ~~issuer’s~~12 ~~classes~~months of(or ~~common~~for ~~stock,~~such asshorter ofperiod that the ~~most~~registrant ~~practicable~~was ~~date:~~required to submit and post such files). Yes ¨ No ¨

Class	Outstanding as of December 11, 2013
Common Stock, $0.001	8,360,000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

2Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

~~ALPHALA~~Indicate by ~~CORP~~check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

PART I	FINANCIAL INFORMATION
ITEM 1	Unaudited Financial Statements	4
	Balance Sheets	4
	Statements of Operations	5
	Statements of Cash Flows	6
	Notes to Unaudited Financial Statements	7
ITEM 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	11
ITEM 4	Controls and Procedures	11
PART II	OTHER INFORMATION	12
ITEM 1	Legal Proceedings	12
ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	12
ITEM 3	Defaults Upon Senior Securities	12
ITEM 4	Mine Safety Disclosures	12
ITEM 5	Other Information	12
ITEM 6	Exhibits	13

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

3PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

~~PART~~Indicate by Icheck mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.~~FINANCIAL~~ ~~INFORMATION~~Yes ¨ No ¨

APPLICABLE ONLY TO CORPORATE ISSURS:

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. 250,800,000 as of February 12, 2015.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	5
Item 4.	Controls and Procedures	5

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	5
Item 1A.	Risk Factors	5
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5
Item 3.	Defaults Upon Senior Securities	6
Item 4.	Mine Safety Disclosures	6
Item 5.	Other Information	6
Item 6.	Exhibits	6

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

FV PHARMA INTERNATIONAL CORP.

Condensed Financial Statements

(UNAUDITED)

TABLE OF CONTENTS

		Page
CONDENSED UNAUDITED FINANCIAL STATEMENTS

Condensed Balance Sheets at October 31, 2014 and January 31, 2014		F - 1

Condensed Statements of Operations for the three and nine month periods ended October 31, 2014 and 2013		F - 2

Condensed Statements of Cash Flows for the nine month periods ended October 31, 2014 and 2013		F - 3

Notes to Condensed Unaudited Financial Statements		F - 4

PART I .FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

ALPHALA CORP. (A DEVELOPMENT STAGE COMPANY) BALANCE SHEETS
		October 31, 2013 (Unaudited)	January 31,2013 (Audited)
ASSETS
Current Assets
	Cash	$ 2,480	$ 31,560
	Prepaid expenses	4,333	-
	Total current assets	6,813	31,560
Total Assets		$ 6,813	$ 31,560
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
	Loan from related party	$ 2,200	$ 200
	Income taxes payable	88	352
	Total current liabilities	2,288	552
Total Liabilities		2,288	552
Stockholders’ Equity
	Common stock, $0.001 par value, 75,000,000 shares authorized;
	8,360,000 shares issued and outstanding at October 31 and January 31, 2013	8,360	8,360
	Additional paid-in-capital	21,240	21,240
	(Deficit) retained earnings accumulated during development stage	(25,075)	1,408
Total Stockholders’ Equity		4,525	31,008
Total Liabilities and Stockholders’ Equity		$ 6,813	$ 31,560

FV PHARMA INTERNATIONAL CORP.

~~The~~CONDENSED ~~accompanying~~BALANCE ~~notes are an integral part of these financial statements.~~SHEETS

4(UNAUDITED)

ALPHALA CORP. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF OPERATIONS (UNAUDITED)
		October 31, 2014				January 31, 2014
	Three months ended October 31, 2013	Three months ended October 31, 2012	Nine months ended October 31, 2013	For the period from Inception (February 9, 2012) to October 31, 2012	For the period from Inception (February 9, 2012) to October 31, 2013
		(unaudited)
Revenues	$ -	$ -	$ -	$ -	$2,475
ASSETS
Operating expenses
Current Assets
General and administrative	14,662	98	26,483	141	27,462
Cash		$	-			$	3,919
Total operating expenses	14,662	98	26,483	141	27,462
Prepaid expenses			-				2,333
Net income (loss) from operations	(14,662)	(98)	(26,483)	(141)	(24,987)
Income taxes receivable			264				264
Provision for income taxes	-	-	-	-	88
Total current assets			264				6,516
Net income (loss)	$ (14,662)	$ (98)	$(26,483)	$ (141)	$(25,075)
Total assets		$	264			$	6,516
Loss per share – Basic and Diluted	$ (0.00)*	$(0.00)*	$(0.00)*	$(0.00)*
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Weighted Average Shares-Basic and Diluted	8,360,000	655,435	8,360,000	226,692
Current Liabilities
Due to related party		$	25,243			$	-
Accounts payable			10,965				-
Total current liabilities			36,208				-
Total liabilities			36,208				-
Stockholders’ Equity (Deficit)
Common stock, $0.001 par value, 750,000,000 shares authorized; 250,800,000 shares issued and outstanding			250,800				250,800
Additional paid-in-capital			(215,400	)			(215,400	)
Accumulated deficit			(71,344	)			(28,884	)
Total stockholders’ equity (deficit)			(35,944	)			6,516
Total liabilities and stockholders’ equity (deficit)		$	264			$	6,516

The accompanying notes are an integral part of these condensed unaudited financial statements.

F-1

FV PHARMA INTERNATIONAL CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three months ended October 31, 2014			Three months ended October 31, 2013			Nine months ended October 31, 2014			Nine months ended October 2013
Revenues	$	-		$	-		$	-		$	-

Operating expenses
General and administrative		1,219			14,662			42,460			26,483

Total operating expenses		1,219			14,662			42,460			26,483

Net income (loss) from operations		(1,219	)		(14,662	)		(42,460	)		(26,483	)
Provision for income taxes		-			-			-			-

Net income (loss)	$	(1,219	)	$	(14,662	)	$	(42,460	)	$	(26,483	)
Loss per share – Basic and Diluted	$	(0.00	)*	$	(0.00	)*	$	(0.00	)*	$	(0.00	)*

Weighted Average Shares-Basic and Diluted		250,800,000			8,360,000			250,800,000			8,360,000

‘* denotes a loss of less than $(0.01) per share

The accompanying notes are an integral part of these financial statements.

5F-2

ALPHALA CORP. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF CASH FLOWS (UNAUDITED)
		Nine months ended October 31, 2013	For the period from inception (February 9, 2012) to October 31, 2012	For the period from inception (February 9, 2012) to October 31, 2013
Operating Activities
	Net income (loss)	$ (26,483)	$ (141)	$ (25,075)
	Changes in Operating Assets and Liabilities: Prepaid Expenses	(4,333)	-	(4,333)
	Income tax payable	(264)	-	88
	Net cash used in operating activities	(31,080)	(141)	(29,320)
Investing Activities		-	-	-
Financing Activities
	Proceeds from issuance of common stock	-	7,000	29,600
	Proceeds from loan from related party	2,000	200	2,200
	Net cash provided by financing activities	2,000	7,200	31,800
Net increase (decrease) in cash		(29,080)	7,059	2,480
Cash at beginning of the period		31,560	-	-
Cash at end of the period		$ 2,480	$ 7,059	$ 2,480
	Supplemental cash flow information:
	Cash paid for:
	Interest	$ -	$ -	$ -
	Taxes	$ -	$ -	$ -

FV PHARMA INTERNATIONAL CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine months ended October 31, 2014			Nine months ended October 31, 2013
Operating Activities
Net income (loss)	$	(42,460	)	$	(26,483	)
Changes in Operating Assets and Liabilities: Prepaid Expenses		2,333			(4,333	)
Income tax payable		-			(264	)
Accounts payable		10,965
Related party payable		25,243
Net cash used in operating activities		(3,919	)		(31,080	)

Investing Activities		-			-

Financing Activities
Proceeds from issuance of common stock		-
Proceeds from loan from related party		-			2,000
Net cash provided by financing activities		-			2,000

Net increase (decrease) in cash		(3,919	)		(29,080	)

Cash at beginning of the period		3,919			31,560

Cash at end of the period	$	-		$	2,480
Supplemental cash flow information:
Cash paid for:
Interest	$	-		$	-
Taxes	$	-		$	-

The accompanying notes are an integral part of these financial statements.

6F-3

~~ALPHALA~~FV PHARMA INTERNATIONAL CORP.

(ANOTES ~~DEVELOPMENT~~TO ~~STAGE~~THE ~~COMPANY)~~FINANCIAL STATEMENTS

~~NOTES~~OCTOBER TO31, ~~THE UNAUDITED FINANCIAL STATEMENTS~~ 2014

~~FOR THE THREE MONTHS ENDED OCTOBER 31, 2013 AND 2012, AAND~~(UNAUDITED)

~~THE~~NOTE ~~NINE~~1 ~~MONTHS~~– ~~ENDED~~ORGANIZATION ~~OCOBER 31, 2013~~ AND ~~THE PERIOD FROM INCEPTION (FEBRUARY 9, 2012) TO OCTOBER 31, 2012~~BUSINESS OPERATIONS

NOTE 1 - ORGANIZATION AND BUSINESS OPERATIONS

Organization and Description of Business

~~ALPHALA~~FV ~~CORP~~Pharma International Corp. (the “Company”) was incorporated under the laws of the State of Nevada on February 9, 2012 (Inception) and plans to commence operation in the distribution of teeth whitening products. The Company is in the development stage as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915-205 "Development-Stage Entities.” For the period from Inception (February 9, 2012) through October 31, 2013 the Company has accumulated losses of $25,075.

~~NOTE~~On 2July 10, 2014, Alphala Corp. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Amendment”) with the State of Nevada to change its corporate name from “Alphala Corp” to “FV Pharma International Corp.” A copy of the Amendment was attached to the Report on Form 8-K ~~SUMMARY~~as OFExhibit ~~SIGNIFICANT~~3.1 ~~ACCOUNTING~~filed ~~POLICIES~~on August 12, 2014.

The Company informed the Financial Industry Regulatory Authority (“FINRA”) of such corporate name change and requested a symbol change from “ALPC” to “FVPI” corresponding to the corporate name change. On August 5, 2014, FINRA announced the corporate name change and symbol change and both corporate actions took effect on August 6, 2014.

On June 10, 2014, Alphala Corp. (the “Company”) entered into a non-binding letter of intent (the “LOI”) with FV Pharma Inc., a private Ontario, Canada corporation (“FV Pharma”), and all the holders of the Class B non-voting shares of FV Pharma (the “Shares”), pursuant to which the Company agreed to acquire 100% of the Shares from such holders in exchange for the allotment and issuance of 150,000,000 restricted shares of the Company’s common stock (the “Transaction”). The Transaction is expected to take the form of a share exchange with the result that FV Pharma will become a partially owned subsidiary of the Company, and is subject to certain closing conditions, including the completion of satisfactory due diligence by the parties, the negotiation of satisfactory transaction documentation, the approval of the Transaction by the respective boards of directors of FV Pharma and the Company and the delivery to the Company of audited financial statements of FV Pharma for its two most recent fiscal years. The LOI was terminated on August 25, 2014 because the letter was not executed.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited ~~financial~~condensed financial statements have been prepared in accordance with generally accepted accounting principles as promulgated in the United States of America (“U.S. GAAP”) and the instructions from Regulation S-X and do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. All adjustments which are, in the opinion of management, necessary for a fair presentation of the results of operations for the interim period(s), and to make the financial statements not misleading, have been made and are of a recurring nature unless otherwise disclosed herein. The results of operations for such interim period(s) are not necessarily indicative of operations for a full year.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.

The Company'’s bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At October 31, 2014 and January 31,~~2013~~ 2014, the Company'’s bank deposits did not exceed the insured amounts.

F-4

Basic and Diluted Income (Loss) Per Share

The Company computes loss per share in accordance with ~~“FASB~~ ASC 260”, “Earnings per Share”, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. No potentially dilutive debt or equity instruments were issued of outstanding during the three month periods ended October 31, 2014 or 2013.

No potential dilutive securities have been issued and outstanding during the period from Inception (February 9, 2012) to October 31, 2013.

Income Taxes

The Company ~~follows~~accounts ~~the~~for ~~liability~~income ~~method~~taxes ofpursuant to ~~accounting~~ASC ~~for~~740, ~~income~~“Income ~~taxes~~Taxes”. Under ~~this~~ASC ~~method~~740, deferred income taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and ~~liabilities~~operating loss carryforwards and deferred tax liabilities are recognized for ~~the~~taxable ~~estimated~~temporary ~~tax~~differences. ~~consequences~~Temporary ~~attributable~~differences toare the differences between the ~~financial~~reported ~~statement~~amounts ~~carrying~~of ~~values~~assets and liabilities and their ~~respective~~tax ~~income~~bases. Deferred tax ~~basis~~assets ~~(temporary~~are ~~differences). The~~reduced ~~effect~~by ona valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The provision for income taxes represents the tax ~~assets~~expense ~~and~~for ~~liabilities~~the ofperiod, aif any, and the change during the period in deferred tax ~~rates~~assets isand ~~recognized~~liabilities. inDeferred tax ~~income~~assets inand ~~the~~liabilities ~~period~~are ~~that~~adjusted ~~includes~~for the ~~enactment~~effects of changes in tax laws and rates on the date. of enactment.

F-5

FV PHARMA INTERNATIONAL CORP.

NOTES TO THE FINANCIAL STATEMENTS

OCTOBER 31, 2014

(UNAUDITED)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Income Taxes (continued)

ASC 740 also provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax positions. Under ASC 740, the impact of an uncertain tax position on the income tax return may only be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. At October 31, 2014 and January 31, 2014, there were no unrecognized tax benefits.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 605, “Revenue Recognition”. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectibility is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectibility of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

Advertising Costs

The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expense of $0 during the three ~~and nine~~ month periods ended October 31, ~~2013~~2014 and ~~the three month period ended October 31, 2012 and the period from Inception (February 9, 2012) to October 2012~~2013.

Recent Accounting Pronouncements

~~The~~Management ~~Company~~does ~~has~~not ~~reviewed~~believe ~~all~~that ~~the~~any ~~recent accounting pronouncements~~ recently issued ~~to date of the issuance of these financial statements~~, ~~and~~but ~~does~~ not ~~believe~~yet ~~any~~effective, ofaccounting ~~these~~standards, ~~pronouncements~~if adopted, will have a material ~~impact~~effect on the ~~company~~Company’s condensed financial statements.

Fair Value of Financial Instruments

~~“FASB~~ ASC 820”, "“Fair Value Measurements and Disclosures"”, establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amounts of financial assets and liabilities, such as cash, prepaid expenses, ~~loans~~income ~~from~~taxes ~~related~~receivable, ~~party~~accounts payable and ~~income~~due ~~taxes~~to ~~payable~~related party approximate their fair values because of the short maturity of these instruments.

F-6

FV PHARMA INTERNATIONAL CORP.

NOTES TO THE FINANCIAL STATEMENTS

OCTOBER 31, 2014

(UNAUDITED)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of Estimates

The preparation of financial statements in conformity with ~~generally~~U.S. ~~accepted~~GAAP ~~accounting principles~~ requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 3 – ~~COMMON~~GOING ~~STOCK~~CONCERN

The accompanying condensed unaudited financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has 75incurred a loss since Inception (February 9,~~000~~ 2012) resulting in an accumulated deficit of $71,~~000~~344 ~~common~~as ~~shares~~of ~~authorized~~October ~~with~~31, a2014, ~~par~~and ~~value~~further losses are anticipated in the development of $0its business.~~001~~ ~~per~~Accordingly, ~~share.~~there is substantial doubt about the Company’s ability to continue as a going concern.

OnThe ~~October~~ability ~~22,~~to ~~2012,~~continue as a going concern is dependent upon the Company ~~issued~~generating ~~6,000,000~~profitable ~~shares~~operations ofin the future and/ or obtaining the necessary financing to meet its ~~common~~obligations ~~stock~~and atrepay ~~$0.001~~its ~~per~~liabilities ~~share~~arising ~~for~~from ~~total~~normal ~~proceeds~~business ofoperations ~~$6,000.~~when they come due.

~~For~~NOTE ~~the period from October 29, 2012 to December~~ 4, ~~2012,~~– ~~the~~COMMON ~~Company issued 2,360,000 shares of its common stock at $0.01 per share for total proceeds of $23,600.~~STOCK

~~The~~Common ~~total number of shares issued and outstanding at October 31, 2013 was 8,360,000.~~Stock

~~NOTE~~The 4Company –has ~~RELATED~~750,000,000 ~~PARTY~~shares ~~TRANSACTIONS~~of common stock authorized with a par value of $0.001 per share.

~~Since~~On ~~Inception~~October ~~(February 9~~22, 2012~~) through October 31~~, ~~2013 a director and shareholder of~~ the Company ~~has~~issued ~~loaned the Company $2~~180,~~200~~000,000 shares ~~to pay for incorporation costs and operating expenses. As~~ of ~~October~~its 31common ~~and~~stock ~~January~~for ~~31, 2013, the~~ total ~~loan~~proceeds ~~amount~~of ~~was~~ $26,~~200~~000. ~~The loan is non-interest bearing, due upon demand and unsecured.~~

~~NOTE~~During 5the –period ~~SUBSEQUENT~~from ~~EVENTS~~October 29, 2012 to December 4, 2012, the Company issued 70,800,000 shares of its common stock for total proceeds of $23,600.

InOn ~~accordance~~April ~~with ASC 855-10~~11,~~Subsequent~~ ~~Events~~2014, the holders of a majority of the Company’s ~~has~~issued ~~analyzed~~and outstanding common stock approved an increase in its ~~operations~~authorized ~~subsequent~~capital tofrom ~~October~~75,000,000 31shares of common stock, ~~2013~~par tovalue ~~the~~$0.001, ~~date~~to ~~these~~750,000,000 ~~financial~~shares ~~statements~~of ~~were~~common ~~issued~~stock, ~~and~~par ~~has~~value ~~determined~~$0.001 ~~that~~(the it“Authorized ~~does~~Capital ~~not~~Increase”). The ~~have~~purpose ~~any~~of ~~material~~the ~~subsequent~~Authorized ~~events~~Capital Increase was to ~~disclose~~reorganize the Company’s capital structure in ~~these~~connection ~~financial~~with ~~statements~~the stock dividend described below. The Company formally effected the Authorized Capital Increase on April 11, 2014 by filing a Certificate of Amendment with the Nevada Secretary of State.

On April 14, 2014, the Company’s sole director approved a stock dividend of 29 authorized but unissued shares of common stock on each one (1) pre-dividend issued and outstanding share of the Company’s common stock. On May 1, 2014, the Company received approval from the Financial Industry Regulatory Authority (FINRA) to effect the stock dividend by way of a forward split, and on the same date, the Company’s shareholders of record on April 25, 2014 received the dividend. As a result of the stock dividend, the Company’s issued and outstanding common stock increased from 8,360,000 (pre-dividend) shares to 250,800,000 (post-dividend) shares. All references to common stock have been reflected retroactively.

~~FORWARD LOOKING STATEMENTS~~F-7

~~Statements~~FV ~~made~~PHARMA inINTERNATIONAL this Form 10-Q that are not historical or current facts are "forward-looking statements" made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the "Act") and Section 21E of the Securities Exchange Act of 1934CORP. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

~~ITEM~~NOTES 2.TO ~~MANAGEMENT'S~~THE ~~DISCUSSION AND ANALYSIS OF~~ FINANCIAL ~~CONDITION AND RESULTS OF OPERATION~~STATEMENTS

~~ALPHALA~~OCTOBER ~~CORP. (“the Company”~~31, “we” or “us’ ) was incorporated under the laws of the State of Nevada, U.S. on February 9, 2012. Our registration statement was filed with the Securities and Exchange Commission on April 2, 2013 and was declared effective on June 14, 2013. We are a development stage company which plans to engage in the distribution of teeth whitening strips in Latvia.2014

We expect to be able to purchase our inventory from on-line stores. We will be purchasing our inventory from different online stores. We plan on selling different brands of whitening strips. We will take prepayments from our clients prior to purchasing and shipment. Our customers will be responsible to cover the shipping costs, custom duties, taxes or any other additional charges that might incur. (UNAUDITED)

OnNOTE ~~January~~4 ~~14,~~– ~~2013,~~COMMON weSTOCK ~~executed a Sales Distribution Agreement with Aldent LLC. On January 23, 2013 we filled Aldent's first orders in the amount of $2,475 and shipped teeth whitening to them.~~(continued)

~~RESULTS~~As OFat ~~OPERATION~~October 31, 2014 and January 31, 2014, 250,800,000 shares of common stock were issued and outstanding.

~~Our~~Additional ~~financial~~paid statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in ~~operation.~~Capital

WeFrom ~~expect~~February we9, ~~will~~2012 ~~require~~(Inception) ~~additional~~through ~~capital~~January 31, 2014, the Company’s former sole director and principal shareholder loaned the Company a total of $5,800 to ~~meet~~pay ~~our~~for ~~long~~incorporation costs ~~term~~and operating ~~requirements~~expenses. WeThe ~~expect~~loan towas ~~raise~~non-interest ~~additional~~bearing, ~~capital~~due ~~through,~~upon ~~among~~demand ~~other~~and ~~things~~unsecured. Effective January 31, 2014, the Company’s ~~sale~~former sole director and principal shareholder forgave repayment of ~~equity~~the or$5,800 ~~debt~~outstanding ~~securities~~loan balance which was credited to additional paid in capital at that time.

~~Three~~NOTE ~~Month~~5 ~~Period~~– ~~Ended~~RELATED ~~October~~PARTY ~~31, 2013 Compared to the Three Month Period Ended October 31, 2012.~~TRANSACTIONS

~~Revenue~~In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note.

WeFrom ~~recognized~~February no9, ~~revenue~~2012 in(inception) through January 31, 2014, the ~~three~~Company’s ~~months~~former ~~ended~~sole ~~October~~director and principal shareholder loaned the Company a total of $5,800 to pay for incorporation costs and operating expenses. The loan was non-interest bearing, due upon demand and unsecured. Effective January 31, ~~2013~~2014, the Company’s former sole director and ~~2012~~principal asshareholder weforgave ~~are~~repayment aof ~~development~~the ~~stage~~$5,800 ~~company~~outstanding loan balance which was credited to additional paid in capital at that time.

~~Operating~~As ~~Expenses~~at October 31, 2014, the Company owed $25,243 to its sole director and principal shareholder for expense reimbursements. The loan is non-interest bearing, unsecured and has no specific repayment terms.

~~During~~NOTE ~~the~~6 ~~three~~– ~~month~~INCOME period ended October 31, 2013, we incurred general and administrative expenses of $14,662 compared to $98 incurred during the three month period ended October 31, 2012. General and administrative expenses incurred were generally related to legal, accounting and developmental costs. The increase the the level of expenses between the two periods reflects the increase in our activity between the two periods in implementing our business plan. TAXES

During the period from February 9, 2012 (Inception) through January 31, 2013, the Company recognized a taxable profit of $1,760, accrued a tax liability of $352 and paid $264 tax in respect of this liability during the twelve months ended January 31, 2014.

~~Net~~During ~~Loss~~the twelve months ended January 31, 2014, the Company incurred taxable losses of $30,644. $1,760 of these losses can be carried back to offset the $1,760 taxable profits arising in the period from February 9, 2012 (Inception) through January 31, 2013 and accordingly the Company is entitled to a refund of the $264 of tax paid in respect of this period and to recognize a full credit for the $352 tax liability provided for in the prior period. The remaining balance of $28,884 unrelieved tax losses are potentially available to offset taxable profits the Company may generate in the future.

~~Our~~During ~~net loss for~~ the ~~three~~nine ~~month~~months ~~period~~ ended October 31, ~~2013~~2014 the ~~was~~Company incurred further tax losses of $1442,~~662~~460 ~~compared~~increasing the total available tax losses potentially available to aoffset taxable profits the Company may generate in the future to $71,344. The net operating loss ofcarry ~~$98~~forward ~~during~~will ~~the~~expire ~~three~~between ~~month~~2033 ~~period~~and ~~ended~~2034. This ~~October~~carry ~~31,~~forward ~~2012~~may ~~for~~be limited upon the ~~reasons~~consummation ~~explained~~of ~~above~~a business combination under IRC Section 381.

~~Nine Month Period Ended October 31, 2013 Compared to the Period From Inception (February 9, 2012) to October 31, 2012.~~F-8

~~Revenue~~FV PHARMA INTERNATIONAL CORP.

WeNOTES ~~recognized~~TO noTHE ~~revenue~~FINANCIAL ~~in the nine months ended October 31, 2013 or the period from Inception (February 9, 2012) to October 31, 2012 as we are a development stage company.~~STATEMENTS

~~Operating~~OCTOBER ~~Expenses~~31, 2014

~~During the nine month period ended October 31, 2013, we incurred general and administrative expenses of $26,483 compared to $141 incurred during the period from Inception~~ (~~February 9, 2012~~UNAUDITED) to October 31, 2012. General and administrative expenses incurred were generally related to legal, accounting and developmental costs. . The increase the the level of expenses between the two periods reflects the increase in our activity between the two periods in implementing our business plan.

~~Net~~NOTE ~~Loss~~6 – INCOME TAXES (continued)

~~Our~~When ~~net~~it ~~loss~~is ~~for~~more ~~the~~likely ~~nine~~than ~~month~~not ~~period~~that ~~ended~~a ~~October~~tax asset ~~31,~~cannot ~~2013~~be ~~was~~realized ~~$26~~through future income,~~483~~ ~~compared~~the toCompany must record an allowance against any future potential future tax benefit. The Company provided a full valuation allowance against the net ~~loss~~deferred oftax ~~$141~~asset, ~~during~~consisting ~~the~~of ~~period~~net ~~from~~operating ~~inception~~loss ~~(February~~carry 9forwards, because ~~2012)~~management has determined that it is more likely than not that it will not earn income sufficient to ~~October~~realize ~~31,~~the ~~2012~~deferred tax ~~for~~assets during the ~~reasons~~carry ~~explained~~forward ~~above~~periods.

~~LIQUIDITY~~The ~~AND~~Company ~~CAPITAL~~has ~~RESOURCES~~not taken a tax position that, if challenged, would have a material effect on the financial statements for the three month periods ended October 31, 2014 and 2013 as defined under ASC 740, “Accounting for Income Taxes”. The Company did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of the accumulated deficit on the balance sheet.

AsNOTE at7 ~~October~~– ~~31,~~SUBSEQUENT ~~2013, our current and total assets were $6,813 compared to $31,560 at January 31, 2013. As at October 31, 2013, our current and total liabilities were $2,288 compared to $552 at January 31, 2013.~~ EVENT

~~Stockholders’~~The ~~equity~~Company ~~decreased~~has ~~from~~evaluated ~~$31,008~~all assubsequent events through the date of ~~January~~issuance ~~31,~~of ~~2013~~the toaccompanying ~~$4,525~~condensed asunaudited offinancial ~~October~~statements ~~31,~~and ~~2013~~the Company does not have any material recognizable subsequent events.

~~Cash Flows For the Nine Month Period Ended October 31, 2013 Compared to the Period From Inception (February~~ F-9~~, 2012) to October 31, 2012.~~

~~Cash~~FORWARD-LOOKING ~~Flows from Operating Activities~~STATEMENTS

WeThis ~~have~~quarterly ~~not~~report ~~generated~~contains ~~positive~~forward-looking statements. ~~cash~~All ~~flows~~statements ~~from~~other ~~operating~~than ~~activities.~~statements ~~For~~of ~~the~~historical ~~nine~~fact ~~month~~are ~~period~~“forward-looking ~~ended~~statements”, ~~October~~including ~~31,~~any projections ~~2013~~of earnings, ~~net~~revenues ~~cash~~or ~~flows~~other ~~used~~financial initems; ~~operating~~any ~~activities~~statements ~~was~~of ~~$31~~the plans,~~080~~ ~~consisting~~strategies ofand aobjectives ~~net~~of ~~loss~~management for offuture ~~$26,483,~~operations; ~~an increase~~any instatements ~~prepaid~~concerning ~~expenses~~proposed ofnew $4products,~~333~~ ~~and~~services ~~decrease~~or indevelopments; ~~income~~any ~~tax~~statements ~~payable~~regarding future economic conditions or performance; statements of ~~$264.~~belief; ~~For~~and ~~the~~any ~~period~~statement ~~from~~of ~~Inception~~assumptions ~~(February~~underlying 9,any ~~2012)~~of tothe ~~October~~foregoing. ~~31,~~Such forward-looking ~~2012,~~statements ~~net~~are ~~cash~~subject ~~flows~~to ~~used~~inherent inrisks ~~operating~~and ~~activities~~uncertainties, ~~was~~and ~~$141~~actual ~~consisting~~results ofcould ~~our~~differ ~~net~~materially ~~loss~~from ofthose anticipated ~~$141.~~by any forward-looking statements.

10These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs, and risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements.

~~Cash~~Item ~~Flows~~2. ~~from~~Management’s ~~Investing~~Discussion ~~Activities~~and Analysis of Financial Condition and Results of Operations

WeThe ~~neither~~following ~~generated~~discussion orof ~~used~~our ~~funds~~financial ~~from~~condition and ~~investing~~results ~~activities~~of operations is based upon our financial statements which have been prepared in conformity with accounting principles generally accepted in the ~~nine~~United ~~moths~~States. ~~ended~~It ~~October~~should ~~31,~~be ~~2013~~read orin conjunction with our financial statements, including the ~~period~~notes ~~from~~thereto, that ~~Inception~~appear ~~(February~~elsewhere 9in this quarterly report. The discussion of results, ~~2012)~~causes and trends should not be construed to ~~October~~imply ~~31,~~any conclusion ~~2012~~that these results or trends will necessarily continue into the future.

~~Cash~~As ~~Flows~~used ~~from~~in ~~Financing~~this ~~Activities~~quarterly report, the terms “we”, “us” and “our” mean FV Pharma International Corp. and all dollar amounts refer to U.S. dollars, unless otherwise indicated.

We have financed our operations primarily from tproceeds from the sale of shares of pur common stock and from loans provided to us by our principal shareholder and director . For the nine month period ended October 31, 2013, cash provided by financing activities was $2,000 received from the proceeds from a loan ot us from director our principal shareholder and director. For the period from Inception (February 9, 2012) to October 31, 2012, net cash provided by financing activities was $7,200, $7,000 received from proceeds from sales of shares of our common stock and $200 from a loan from our principal shareholder and director.Overview

~~PLAN~~We OFwere ~~OPERATION~~incorporated ~~AND~~under ~~FUNDING~~the laws of the State of Nevada on February 9, 2012 with plans to engage in the distribution of teeth whitening strips in Latvia. Our registration statement on Form S-1 was declared effective by the Securities and Exchange Commission on June 14, 2013. To date, our business operations have been primarily limited to the development of a business plan, the completion of private placements for the offer and sale of our common stock and the signing of the sales distribution agreement with Aldent LLC, a private Latvian company (“Aldent”), dated January 14, 2013 (the “Sales Distribution Agreement”). On January 23, 2013 we filled Aldent’s first orders and recognized $2,475 in gross profit from the sale transaction.

WeOn ~~expect~~June ~~that~~10, ~~working~~2014, ~~capital~~Alphala ~~requirements~~Corp. ~~will~~(the ~~continue~~“Company”) entered tointo bea ~~funded~~non-binding ~~through~~letter of intent (the “LOI”) with FV Pharma Inc., a ~~combination~~private Ontario, Canada corporation (“FV Pharma”), and all the holders of ~~our~~the ~~existing~~Class ~~funds~~B non-voting shares of FV Pharma (the “Shares”), pursuant to which the Company agreed to acquire 100% of the Shares from such holders in exchange for the allotment and ~~further~~issuance ~~issuances~~of 150,000,000 restricted shares of ~~securities.~~the ~~Our~~Company’s ~~working~~common ~~capital~~stock ~~requirements~~(the ~~are~~“Transaction”). The Transaction is expected to ~~increase~~take inthe form ~~line~~of a share exchange with the ~~growth~~result that FV Pharma will become a partially owned subsidiary of ~~our~~the ~~business~~Company, and is subject to certain closing conditions, including the completion of satisfactory due diligence by the parties, the negotiation of satisfactory transaction documentation, the approval of the Transaction by the respective boards of directors of FV Pharma and the Company and the delivery to the Company of audited financial statements of FV Pharma for its two most recent fiscal years. The LOI was terminated on August 25, 2014 because the letter was not executed.

~~Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next nine months.~~ We ~~have~~cannot nostate ~~lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection~~ with ~~our~~certainty ~~business~~whether plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) acquisition of inventory; (ii) developmental expenses associated with a start-up business; and (iii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we ~~expect we~~ will successfully ~~need~~close tothe ~~raise~~Transaction ~~additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity~~ or ~~convertible~~achieve ~~debt~~profitable ~~securities will result in dilution to our current shareholders~~operations. ~~Further,~~As such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of ~~prospective~~October ~~new business endeavors or opportunities~~31, ~~which~~2014 could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a specific plan of how we ~~will~~had ~~obtain~~minimal ~~such~~assets ~~funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock. We have~~ and ~~will~~had ~~continue~~generated limited ~~to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made~~revenues. ~~We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing.~~

~~OFF-BALANCE SHEET ARRANGEMENTS~~ 2

AsOur ofCorporate the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.History

~~GOING~~On ~~CONCERN~~April 11, 2014, the holders of a majority of our issued and outstanding common stock approved an increase in our authorized capital from 75,000,000 shares of common stock, par value $0.001, to 750,000,000 shares of common stock, par value $0.001 (the “Authorized Capital Increase”). The purpose of the Authorized Capital Increase was to reorganize our capital structure in connection with the stock dividend described below. We formally effected the Authorized Capital Increase on April 11, 2014 by filing a Certificate of Amendment with the Nevada Secretary of State.

~~The~~On ~~independent~~April ~~auditors'~~14, ~~report~~2014, ~~accompanying~~ our ~~January~~sole ~~31,~~director ~~2013~~approved a ~~financial~~stock ~~statements~~dividend ~~contained~~of an29 ~~explanatory~~authorized ~~paragraph~~but ~~expressing~~unissued ~~substantial~~shares ~~doubt~~of ~~about~~ our ~~ability~~common tostock ~~continue~~on aseach aone ~~going~~(1) ~~concern.~~issued ~~The~~and ~~financial~~outstanding ~~statements~~share ~~have~~of ~~been~~our ~~prepared~~common stock. ~~"assuming~~On ~~that~~May 1, 2014, we ~~will~~received ~~continue~~approval asfrom the Financial Industry Regulatory Authority (FINRA) to effect the stock dividend by way of a ~~going~~forward ~~concern~~split," ~~which~~and ~~contemplates~~on ~~that~~the wesame ~~will~~date, ~~realize~~ our ~~assets~~shareholders ~~and~~of ~~satisfy~~record on April 25, 2014 received the dividend. As a result of the stock dividend, our ~~liabilities~~issued and ~~commitments~~outstanding common stock increased from 8,360,000 (pre-dividend) shares to 250,800,000 (post-dividend) shares. All references to our common stock in ~~the~~this ~~ordinary~~quarterly ~~course~~report ofhave ~~business~~been reflected retroactively.

~~ITEM~~Results 3.of ~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.~~Operations

~~As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.~~ Revenues

11We did not generate any revenues during the three months ended October 31, 2014 or 2013. Since our inception on February 2, 2009 we have generated $2,475 in revenues, all of which was attributable to a single purchase and sale transaction with Aldent. Our ability to generate any revenues during the next 12 months is uncertain.

~~ITEM 4. CONTROLS AND PROCEDURES~~Expenses

~~Our~~During ~~management~~the isthree ~~responsible~~months ~~for~~ended ~~establishing~~October ~~and~~31, ~~maintaining~~2014, we aincurred ~~system~~$1,219 ofin ~~disclosure~~operating ~~controls~~expenses, ~~and~~all ~~procedures~~of ~~(as~~which ~~defined~~were ingeneral ~~Rule~~and ~~13a-15(e)~~administrative ~~and~~in ~~15d-15(e)~~nature. ~~under~~During the ~~Exchange~~same ~~Act)~~period ~~that is designed to ensure that information required to be disclosed by us~~ in the prior ~~reports~~year, ~~that~~ we ~~file~~incurred or$14,662 ~~submit~~in ~~under~~operating ~~the~~expenses, ~~Exchange~~all ~~Act~~of iswhich ~~recorded,~~were ~~processed,~~general ~~summarized~~ and ~~reported,~~administrative ~~within the time periods specified~~ in ~~the Commission’s rules and forms~~nature. ~~Disclosure~~The ~~controls~~increase ~~and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer~~ in our ~~the~~operating ~~reports~~expenses ~~that~~between ~~it files or submits under~~ the ~~Exchange~~two ~~Act~~years iswas ~~accumulated~~primarily ~~and~~attributable ~~communicated~~ to ~~the~~our ~~issuer’s~~transition ~~management,~~from ~~including~~a ~~its~~private ~~principal~~to ~~executive~~a ~~officer~~public orcompany ~~officers~~ and our ~~principal~~associated ~~financial~~reporting ~~officer~~requirements orunder ~~officers,~~applicable orsecurities ~~persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure~~laws.

AnNet evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of October 31, 2013. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the nine-month period ended October 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.Loss

~~PART~~During ~~II.~~the ~~OTHER~~three ~~INFORMATION~~months ended October 31, 2014, we incurred a net loss of $1,219, whereas during the same period in the prior year we incurred a net loss of $14,662 due to the factors described above.

~~ITEM~~Nine 1.Month ~~LEGAL~~Period ~~PROCEEDINGS~~Ended October 31, 2013 Compared to the Nine Month Period Ended October 31, 2014.

~~Management~~Our isnet ~~not~~loss ~~aware~~for ofthe ~~any~~nine ~~legal~~month ~~proceedings~~period ~~contemplated~~ended byOctober ~~any~~31, ~~governmental~~2014 ~~authority~~was $42,460 orcompared ~~any~~to ~~other~~a ~~party~~net ~~involving~~loss usof or$26,483 ~~our~~during ~~properties. As of~~ the ~~date~~nine ofmonth ~~this~~period ~~Quarterly~~ended ~~Report,~~October ~~no director~~31, ~~officer~~2013. orDuring ~~affiliate~~the isnine ~~(i)~~month aperiod ~~party~~ended October ~~adverse~~31, to2014 usand ~~in any legal proceeding~~2013, orwe ~~(ii)~~did ~~has an adverse interest to us in any legal proceedings. Management is~~ not ~~aware~~generate of any ~~other legal proceedings pending or that have been threatened against us or our properties~~revenue.

~~ITEM~~During 2the nine month period ended October 31, 2014, we incurred general and administrative expenses of $42,460 compared to $26,483 incurred during the nine month period ended October 31, 2013. General ~~UNREGISTERED~~and ~~SALES~~administrative OFexpenses ~~EQUITY~~incurred ~~SECURITIES~~during ~~AND~~the ~~USE~~six OFmonth ~~PROCEEDS~~period ended October 31, 2014 were related to legal, accounting and developmental costs.

OnThe ~~October~~weighted ~~22,~~average ~~2012,~~number ~~the~~of ~~Company issued 6,000,000~~ shares ofoutstanding ~~its~~was ~~common stock at $0.001 per share for total proceeds of $6~~250,~~000. For the period from October 29~~800, ~~2012 to December 4, 2012, the Company issued 2,360,~~000 ~~shares of its common stock at $0.01 per share~~ for ~~total proceeds of $23,600. The sales were exempt under Section 4(2) and 3(b) of~~ the ~~Securities~~nine ~~Act~~month ofperiod ~~1933,~~ended asOctober ~~amended~~31, and the rules and regulations promulgated there under, including Regulations D, due to the facts that the investor was an accredited investor, had acquired the shares for investment purposes and not with a view for re-distribution, had access to sufficient information concerning the Company, and the certificate(s) representing such shares will bear a restrictive legend2014.

~~ITEM~~Liquidity 3.and ~~DEFAULTS~~Capital ~~UPON SENIOR SECURITIES~~Resources

WeAs ~~have~~of noOctober ~~senior~~31, ~~securities~~2014, ~~outstanding~~we had $0 in ~~any~~cash, $264 ofin ~~the~~total ~~periods~~assets, ~~presented~~$36,208 in ~~these~~total ~~financial~~liabilities, ~~statements~~a working capital deficit of $35,944 and an accumulated deficit of $71,344.

~~ITEM~~During 4the three months ended October 31, 2014, we incurred $1,219 in operating expenses which resulted in an increase in the balance due to related party of $3,000 and a net decrease in accounts payable of 1,781. ~~MINE~~During ~~SAFETY~~the ~~DISCLOSURES~~same period in the prior year, we used $14,662 in net cash on operating activities, substantially all of which was attributable to our net loss for the period.

~~Not applicable.~~3

~~ITEM~~During 5the nine months ended October 31, 2014, we incurred $42,460 in operating expenses. ~~OTHER~~During ~~INFORMATION~~the same period in the prior year, we used $26,483 in net cash on operating activities, substantially all of which was attributable to our net loss for the period.

~~Not~~We ~~applicable~~did not generate or use any funds in investing activities during the nine months ended October 31, 2014 or 2013.

12We did not engage in any financing activities during either of the nine month periods ended October 31, 2014 or 2013.

~~ITEM~~Our 6plans for the next 12 months are uncertain due to our current financial condition; however, we intend to raise additional funds through public or private placement offerings. If ~~EXHIBITS~~we are unsuccessful in raising enough money through such efforts, we may review other financing possibilities such as bank loans. At this time we do not have a commitment from any broker-dealer to provide us with financing. There is no assurance that any financing will be available to us or if available, on terms that will be acceptable to us. In the absence of such financing, we may be forced to cease or significantly curtail our operations.

~~Exhibits:~~Going Concern

Our financial statements have been prepared on a going concern basis, which contemplates, among other things, that we will continue to realize our assets and satisfy our liabilities in the normal course of business. As at October 31, 2014, we had a working capital deficit of $35,944 and an accumulated deficit of $71,344.1 We intend to fund our operations through equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital and other cash requirements for the next 12 months.

~~Certification~~Our ofability ~~Chief~~to ~~Executive~~obtain ~~Officer~~ additional financing to continue our operations and ~~Chief~~the ~~Financial~~attainment ~~Officer~~of ~~pursuant~~profitable operations are factors that raise substantial doubt about our ability to ~~Section~~continue ~~302(~~as a) ofgoing concern. Our financial statements do not include any adjustments that might result from the ~~Sarbanes-Oxley Act~~outcome of this uncertainty.

~~32.1~~ Critical Accounting Policies

~~Certification~~ In June 2014, the FASB issued ASU No. 2014-10, which amended Accounting Standards Codification (ASC) Topic 915 Development Stage Entities. The amendment eliminates certain financial reporting requirements surrounding development stage entities, including an amendment to the variable interest entities guidance in ASC Topic 810, Consolidation. The amendment removes the definition of ~~Chief Executive Officer~~ a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and ~~Chief~~ other entities from U.S. GAAP. Consequently, the amendment eliminates the requirements for development stage entities to (1) ~~Financial~~present ~~Officer~~inception-to-date ~~Under~~information ~~Section~~in ~~1350~~the statements of income, cash flows and shareholder equity, (2) label the financial statements as ~~Adopted~~ ~~Pursuant Section~~those ~~906~~of a development stage entity, (3) disclose a description of the ~~Sarbanes-Oxley~~development ~~Act~~stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.

~~101 Interactive~~This ~~data~~amendment ~~files~~is ~~pursuant~~effective tofor ~~Rule~~fiscal ~~405~~years beginning after December 15, 2014, and interim periods therein. Early application of ~~Regulation~~each ~~S-T~~of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued. The Company has made the election to early adopt this amendment effective June 30, 2014 and, as a result, the Company is no longer presenting or disclosing the information previously required under Topic 915. The early adoption was made to reduce data maintenance by removing all incremental financial reporting requirements for development stage entities. The adoption of this amendment alters the disclosure requirements of the Company, but it does not have any material impact on the Company’s financial position or results of operations for the current or any prior reporting periods.

~~SIGNATURES~~Advertising Costs

InOur ~~accordance~~policy ~~with~~regarding ~~the~~advertising ~~requirements~~is ofto ~~the~~expense advertising ~~Exchange~~when ~~Act,~~incurred. ~~the~~We ~~registrant~~incurred ~~caused~~advertising ~~this~~expense ~~report~~of to$0 beduring ~~signed~~the onthree ~~its~~months ~~behalf~~periods byended ~~the~~October ~~undersigned~~31, ~~thereunto~~2014 ~~duly~~and ~~authorized~~2013.

	ALPHALA CORP.
Dated: December 11, 2013	By: /s/ Irina Petrzhikovskaya
	Irina Petrzhikovskaya, President and Chief Executive Officer and Chief Financial Officer

13Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of October 31, 2014. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in rules and forms of the SEC.

Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this annual report, none of our directors, officers or affiliates is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following documents are filed as a part of this quarterly report.

Exhibit Number		Exhibit Description

3.1		Articles of Incorporation filed with the Nevada Secretary of State on February 9, 2012 (1)

3.2		Bylaws (1)

3.3		Certificate of Amendment filed with the Nevada Secretary of State on April 11, 2014 (2)

3.4		Certificate of Amendment filed with the Nevada Secretary of State on July 10, 2014 (3)

10.1		Sales Distribution Agreement with Aldent LLC dated January 14, 2013 (1)

31.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Presentation Linkbase

(1)	Included as an exhibit to our registration statement on Form S-1 filed with the SEC on April 2, 2013.

(2)	Included as an exhibit to our current report on Form 8-K filed with the SEC on April 15, 2014.

(3)	Included as an exhibit to our current report on Form 8-K filed with the SEC on July 10, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 12, 2015	FV PHARMA INTERNATIONAL CORP.

	By:	/s/ Shaikh M. Shami
		Shaikh M. Shami

		President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Secretary, Treasurer, Director

Filing Compare · FV Pharma International Corp.